JC virus antibody testing for patients with MS: a review of the diagnostic accuracy and guidelines
CADTH
Record ID 32014000197
English
Authors' recommendations:
Anti-JCV antibody assays were able to identify anti-JCV antibodies in approximately 50-60% of natalizumab-treated MS patients or MS patients considering treatment with natalizumab. The StratifyJCV test was found to have a low false negative rate when urinary JCV-DNA was used as a positive reference. No evidence-based guidelines and testing algorithms for JCV antibodies in patients with MS were identified.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/march-2013/RC0437%20JC%20Virus%20in%20MS%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- JC Virus
- Multiple Sclerosis
- Enzyme-Linked Immunosorbent Assay
- Leukoencephalopathy, Progressive Multifocal
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.